RGD Reference Report - Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: a possible interaction with polymorphisms in the interleukin 1 beta gene. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: a possible interaction with polymorphisms in the interleukin 1 beta gene.

Authors: Lind, H  Zienolddiny, S  Ryberg, D  Skaug, V  Phillips, DH  Haugen, A 
Citation: Lind H, etal., Lung Cancer. 2005 Dec;50(3):285-90. Epub 2005 Aug 26.
RGD ID: 4143167
Pubmed: PMID:16126303   (View Abstract at PubMed)
DOI: DOI:10.1016/j.lungcan.2005.07.003   (Journal Full-text)

Tobacco smoking is the main risk factor for lung cancer. Only 10-15% of smokers develop lung cancer, suggesting that genetic factors are of importance in determining individual susceptibility to the disease. Several studies in recent years indicate that chronic inflammation is a cofactor in lung carcinogenesis. We have previously reported an association of interleukin 1 beta gene (IL1B) polymorphisms with lung cancer risk. Interleukin-1 receptor antagonist (IL-1Ra) has been implicated in carcinogenesis of different cancer types. IL-1Ra binds competitively to the same membrane receptor as interleukin-1beta (IL-1beta) and thereby acts as an antagonist to the pro-inflammatory actions of IL-1beta. The aim of the study was to examine whether a common VNTR polymorphism in the interleukin 1 receptor antagonist gene (IL1RN) is associated with lung cancer risk. Due to the tight relationship between IL1RN and IL1B, we also explored the possibility of an interaction between the two genes. The study population comprised of 340 non-small cell lung cancer cases and 412 healthy controls of Norwegian origin. Our results indicate that individuals homozygous for the IL1RN*1 allele and carrying the IL1B-31T allele had increased risk of non-small cell lung cancer (odds ratio C/T 3.08; 1.10-8.62 and T/T 5.87; 2.15-16.05). Furthermore, IL1RN*1 carriers had nearly two-fold higher levels of bulky/hydrophobic DNA adducts in the lung. Our findings support the significance of IL1 gene cluster polymorphisms and risk of lung cancer.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
IL1BHumanlung non-small cell carcinoma susceptibilityIAGP DNA:polymorphism: :-31T>C (human)RGD 
IL1RNHumanlung non-small cell carcinoma susceptibilityIAGP DNA:polymorphism (human)RGD 
Il1bRatlung non-small cell carcinoma susceptibilityISOIL1B (Homo sapiens)DNA:polymorphism: :-31T>C (human)RGD 
Il1bMouselung non-small cell carcinoma susceptibilityISOIL1B (Homo sapiens)DNA:polymorphism: :-31T>C (human)RGD 
Il1rnRatlung non-small cell carcinoma susceptibilityISOIL1RN (Homo sapiens)DNA:polymorphism (human)RGD 
Il1rnMouselung non-small cell carcinoma susceptibilityISOIL1RN (Homo sapiens)DNA:polymorphism (human)RGD 

Objects Annotated

Genes (Rattus norvegicus)
Il1b  (interleukin 1 beta)
Il1rn  (interleukin 1 receptor antagonist)

Genes (Mus musculus)
Il1b  (interleukin 1 beta)
Il1rn  (interleukin 1 receptor antagonist)

Genes (Homo sapiens)
IL1B  (interleukin 1 beta)
IL1RN  (interleukin 1 receptor antagonist)


Additional Information